MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1741)	6/6/2007 11:59:55 PM
From: gcrispin	Read Replies (1) of 2240

From MEDX's 10-K: "The study is designed to assess best objective response rate (complete and partial responses) as the primary endpoint. Secondary endpoints include disease control rate (complete and partial responses plus stable disease), progression-free and overall survival, as well as duration of best objective responses. Other supportive Phase II studies using monotherapy in second-line patients with metastatic melanoma are also under way." From the Morgan Stanley update: We believe that ipilimumab will likely meet the criteria defined in the SPA for second line melanoma (which is on totality of data and not only response rates) I have never heard of a SPA agreement written in such a way that it would be based on the "totality of data." If so, wouldn't that be disclosed in SEC documents? Or is Morgan Stanley just saying that secondary endpoints will also be considered in the decision?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next